Definitive Contract 75N91024C00012
Award Date
2/16/24
Potential Completion Date
5/15/25
Potential Value
$353K
Federal Agency
National Cancer Institute
Awardee
Angstrom Research Inc.
Ultimate Awardee
Not listed
NAICS Category
541713 - Research and Development in Nanotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lunenburg, MA 01462, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $399,062 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Avoneaux Medical Institute, LLC for the development of spatial micro-purification technology. The contract was set aside for small businesses and is part of the NCI's broader SBIR program, which funds research and development in support of the NIH and CDC's mission needs. The original solicitation sought proposals on a range of cancer-related topics, including alternatives to cell...
The National Cancer Institute awarded Nzumbe Inc. a $355,000 firm fixed price definitive contract under the Small Business Innovation Research Concept Award program. This program seeks proposals from small businesses for innovative concepts to advance pediatric and rare cancer therapies, diagnostics, or preventatives. Specifically, Nzumbe will demonstrate technical feasibility and proof-of-concept for a highly innovative pediatric or rare cancer idea through preliminary experiments, while also...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI), a civilian agency, to Qana Therapeutics Inc. The $354,672 Firm Fixed Price contract is for the development of therapeutic technologies targeting ferroptosis inducers for the treatment of adrenocortical carcinoma, a rare cancer type. The contract is part of the NCI's SBIR Innovative Concept Award Program, which seeks innovative and potentially transformative technologies for the...
<p>The National Cancer Institute (NCI) awarded a $199,996.00 Firm Fixed Price contract to Operational Technologies Corporation, a minority-owned, small disadvantaged, veteran-owned business, for Research & Development in Biomedical Basic Research. The contract has a completion date of June 22, 2014 and was set aside for small businesses. As a civilian agency, the NCI focuses on cancer research and this contract contributes to their broader medical research initiatives.</p>
This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...